Guidelines for the Management of Sexually Transmitted Infections. February 2004
(2004; 88 pages)
Table of Contents
View the documentPREFACE
Close this folder1. INTRODUCTION
View the document1.1. Background
View the document1.2. Rationale for standardized treatment recommendations
View the document1.3. Case management
View the document1.4. Syndromic management
View the document1.5. Risk factors for STI-related cervicitis
View the document1.6. Selection of drugs
Open this folder and view contents2. TREATMENT OF STI-ASSOCIATED SYNDROMES
Open this folder and view contents3. TREATMENT OF SPECIFIC INFECTIONS
Open this folder and view contents4. KEY CONSIDERATIONS UNDERLYING TREATMENTS
Open this folder and view contents5. PRACTICAL CONSIDERATIONS IN STI CASE MANAGEMENT
Open this folder and view contents6. CHILDREN6, ADOLESCENTS AND SEXUALLY TRANSMITTED INFECTIONS
View the documentANNEX. LIST OF PARTICIPANTS
 

1.6. Selection of drugs

Antimicrobial resistance of several sexually transmitted pathogens has been increasing in many parts of the world and this has rendered some low-cost regimens ineffective. Recommendations to use more effective drugs frequently raise concerns about cost and possible misuse.

A two-tier drug policy with the provision of less effective drugs at the peripheral health care level and the most effective and usually more expensive drugs only at a referral level may result in an unacceptable rate of treatment failures, complications and referrals, and may erode confidence in health services. This approach is not recommended. The drugs used for STI in all health care facilities should be at least 95% effective. Criteria for the selection of drugs are listed in the box below.

Criteria for the selection of STI drugs

Drugs selected for treating STI should meet the following criteria:

• high efficacy (at least 95%)
• low cost
• acceptable toxicity and tolerance
• organism resistance unlikely to develop or likely to be delayed
• single dose
• oral administration
• not contraindicated for pregnant or lactating women.

Appropriate drugs should be included in the national Essential Drugs list and in choosing drugs, consideration should be given to the capabilities and experience of health personnel.

 

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 1, 2019